Allogene Therapeutics, Inc. (ALLO) Misses Q1 EPS by 6c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q1 EPS of ($0.68), $0.06 worse than the analyst estimate of ($0.62). Revenue for the quarter came in at $50 thousand versus the consensus estimate of $9.73 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Piper Sandler sees Google TPU sales hitting $104BN by 2028
• Zhibao Technology to acquire Malaysian AI computing firm Nexsys Tech
• RBC Capital on AAR Corporation (AIR): 'Fiscal 1Q27 results could deliver upside'